Whitehead RE - Search Results

1

Dopamine transporter immunoreactivity in monkey cerebral cortex: regional, laminar, and ultrastructural localization.

Lewis DA, Melchitzky DS, Sesack SR, Whitehead RE, Auh S, Sampson A. Lewis DA, et al. Among authors: whitehead re. J Comp Neurol. 2001 Mar 26;432(1):119-36. doi: 10.1002/cne.1092. J Comp Neurol. 2001. PMID: 11241381

2

A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia.

Woo TU, Whitehead RE, Melchitzky DS, Lewis DA. Woo TU, et al. Among authors: whitehead re. Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5341-6. doi: 10.1073/pnas.95.9.5341. Proc Natl Acad Sci U S A. 1998. PMID: 9560277 Free PMC article.

3

Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects.

Akil M, Pierri JN, Whitehead RE, Edgar CL, Mohila C, Sampson AR, Lewis DA. Akil M, et al. Among authors: whitehead re. Am J Psychiatry. 1999 Oct;156(10):1580-9. doi: 10.1176/ajp.156.10.1580. Am J Psychiatry. 1999. PMID: 10518170

4

Localized decrease in serotonin transporter-immunoreactive axons in the prefrontal cortex of depressed subjects committing suicide.

Austin MC, Whitehead RE, Edgar CL, Janosky JE, Lewis DA. Austin MC, et al. Among authors: whitehead re. Neuroscience. 2002;114(3):807-15. doi: 10.1016/s0306-4522(02)00289-0. Neuroscience. 2002. PMID: 12220580

5

Effects of D2 dopamine receptor antagonists on Fos protein expression in the striatal complex and entorhinal cortex of the nonhuman primate.

Deutch AY, Lewis DA, Whitehead RE, Elsworth JD, Iadarola MJ, Redmond DE Jr, Roth RH. Deutch AY, et al. Among authors: whitehead re. Synapse. 1996 Jul;23(3):182-91. doi: 10.1002/(SICI)1098-2396(199607)23:3<182::AID-SYN7>3.0.CO;2-4. Synapse. 1996. PMID: 8807746

6

Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents.

Haupt DW, Rosenblatt LC, Kim E, Baker RA, Whitehead R, Newcomer JW. Haupt DW, et al. Am J Psychiatry. 2009 Mar;166(3):345-53. doi: 10.1176/appi.ajp.2008.08030383. Epub 2009 Jan 15. Am J Psychiatry. 2009. PMID: 19147694

7

Predictors of aripiprazole treatment continuation in hospitalized patients.

Coley KC, Fabian TJ, Kim E, Ammerman DK, Scipio TM, Saul MI, Kim MS, Whitehead R, Ganguli R. Coley KC, et al. J Clin Psychiatry. 2008 Sep;69(9):1393-7. doi: 10.4088/jcp.v69n0906. Epub 2008 Sep 9. J Clin Psychiatry. 2008. PMID: 19012819

8

The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia.

Meyer JM, Rosenblatt LC, Kim E, Baker RA, Whitehead R. Meyer JM, et al. J Clin Psychiatry. 2009 Mar;70(3):318-25. doi: 10.4088/jcp.08m04267. Epub 2008 Dec 16. J Clin Psychiatry. 2009. PMID: 19192469

9

Metabolic adverse events in patients with mental illness treated with antipsychotics: a primary care perspective.

Balf G, Stewart TD, Whitehead R, Baker RA. Balf G, et al. Prim Care Companion J Clin Psychiatry. 2008;10(1):15-24. doi: 10.4088/pcc.v10n0104. Prim Care Companion J Clin Psychiatry. 2008. PMID: 18311417 Free PMC article.

10

Comparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials.

Kane JM, Kim E, Kan HJ, Guo Z, Bates JA, Whitehead R, Pikalov A. Kane JM, et al. Appl Health Econ Health Policy. 2009;7(2):109-19. doi: 10.1007/BF03256145. Appl Health Econ Health Policy. 2009. PMID: 19731968 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

34 results

Search Page

Filters